Liquidia Corp (LQDA) Form 8-K — Oct 13, 2026
Liquidia has entered a global settlement with United Therapeutics resolving all six pending lawsuits, including patent infringement claims over the '327 patent that UTHR won on September 30, 2026. Liquidia keeps the right to commercialize YUTREPIA for PAH but must remove the PH-ILD indication from the label and cease all PH-ILD promotion. The deal costs Liquidia a net $380.7 million: $175.0 million to UTC within 30 business days, $145.4 million in two $72.7 million installments in early 2027, plus $60.3 million to settle Sandoz, Henderson, and PBM interests in the related antitrust litigation.
Key figures
- Revenue
- 222700000
- Cash Position
- 396100000
- Pbm payment
- $19.45 million
- Q3 2026 period
- preliminary, unaudited
- Sandoz payment
- $21.75 million
- Utc net payment
- $175.0 million due within 30 business days
- Henderson payment
- $19.05 million
- Utc installment payments
- $145.4 million in two equal installments of $72.7 million (Jan 31, 2027 and Apr 30, 2027)
- Total settlement payments
- net $380.7 million
- Minimum cash covenant increased to
- $45.0 million
- Minimum cash covenant increased from
- $15.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.